Processing

Please wait...

Settings

Settings

1. WO2020059841 - THERAPEUTIC AGENT FOR PRION DISEASES

Publication Number WO/2020/059841
Publication Date 26.03.2020
International Application No. PCT/JP2019/036887
International Filing Date 20.09.2019
Chapter 2 Demand Filed 04.02.2020
IPC
C07D 257/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
257Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
02not condensed with other rings
04Five-membered rings
A61K 31/495 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/5377 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07D 295/135 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
295Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
04with substituted hydrocarbon radicals attached to ring nitrogen atoms
12substituted by singly or doubly bound nitrogen atoms
135with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Applicants
  • 国立大学法人 長崎大学 NAGASAKI UNIVERSITY [JP/JP]; 長崎県長崎市文教町1-14 1-14, Bunkyomachi, Nagasaki-shi, Nagasaki 8528521, JP
Inventors
  • 石橋 大輔 ISHIBASHI, Daisuke; JP
  • 西田 教行 NISHIDA, Noriyuki; JP
  • 水田 賢志 MIZUTA, Satoshi; JP
  • 石川 岳志 ISHIKAWA, Takeshi; JP
Agents
  • 高島 一 TAKASHIMA, Hajime; JP
Priority Data
2018-17722421.09.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) THERAPEUTIC AGENT FOR PRION DISEASES
(FR) AGENT THÉRAPEUTIQUE POUR MALADIES À PRIONS
(JA) プリオン病治療薬
Abstract
(EN)
The purpose of the invention is to provide a compound which has the effect of suppressing abnormal prion production and is useful as a therapeutic agent for prion diseases. Provided are a compound represented by formula (I) (the symbols in the formula are described in the description) or a salt thereof, and a therapeutic agent for prion diseases, the therapeutic agent containing the compound as an active ingredient.
(FR)
L'objectif de l'invention est de fournir un composé qui a pour effet de supprimer la production anormale de prions et qui est utile en tant qu'agent thérapeutique pour des maladies à prions. L'invention concerne un composé représenté par la formule (I) (les symboles dans la formule sont décrits dans la description) ou un sel de celui-ci, et un agent thérapeutique pour les maladies à prions, l'agent thérapeutique contenant le composé en tant que principe actif.
(JA)
異常型プリオンの産生抑制効果を有し、プリオン病治療薬等として有用である化合物を提供すること。式(I):[式中、各記号は、明細書に記載の通りである。] で表される化合物またはその塩、および当該化合物を有効成分として含有するプリオン病治療薬。
Latest bibliographic data on file with the International Bureau